Independent from Merck, Organon CEO lays out newco's women's health ambitions, M&A plans

Big Pharma companies have been backing away from women’s health in recent years, with Merck & Co. being the latest example. But to the CEO of Organon, the newly formed company that’s built upon that portfolio and others from Merck, now is the perfect time to launch a drugmaker specializing in the field.